• br Ghrelin actions in the central nervous

  2022-04-19

  

  Ghrelin actions in the central nervous system Ghrelin induces thymopoeisis GHS-R1a is expressed in immune cells, including thymocytes and T-cells [13]. Infusion of ghrelin increases the number of thymocytes and thymus size in 14-, 20-, and 24-month-old mice, and with decreased thymic adiposity

• We are aware that the classical biochemical view

  2022-04-19

  

  We are aware that the classical biochemical view is centered on the local concentrations of specific ion and molecules rather than on cell electric potentials. However, important downstream processes can be influenced by acting locally on these potentials because they regulate the conductance of the

• br Presenilins in protein trafficking proteolysis and

  2022-04-19

  

  Presenilins in protein trafficking, proteolysis and degradation An obvious explanation for the role of presenilins and γ-secretase in protein trafficking and degradation is that many reported γ-secretase substrates are functionally involved in protein transport. For example, members of the mammal

• FXR agonists represent an attractive class of drugs for pati

  2022-04-19

  

  FXR agonists represent an attractive class of drugs for patients with PFIC. Synthetic and semi-synthetic FXR agonists, with higher affinity and potency to activate FXR, have been successfully tested in animal models of cholestasis. In these murine models, the semi-synthetic steroidal FXR ligand obet

• Statins are recognized by their nephroprotective effect Chmi

  2022-04-19

  

  Statins are recognized by their nephroprotective effect (Chmielewski et al., 2002). The hepato- and nephroprotective effects of silymarin are also well studied (Alqasoumi, 2014, Mohamed et al., 2018). Several studies documented increasing 1,4-DPCA of FXR by statins (Byun et al., 2014& (Lu et al., 2

• Recently there are only a

  2022-04-19

  

  Recently, there are only a spot of FFA4 agonists reported in the literature (Fig. 1),13, 14, 15 and there is no selective FFA4 agonists have reached clinical trial for the treatment of T2DM. TUG-891, the first potent and selective FFA4 agonist, was developed in University of Southern Denmark as a wi

• Lentiviruses are associated with immunological impairment in

  2022-04-19

  

  Lentiviruses are associated with immunological impairment in their respective hosts, and both human immunodeficiency and feline immunodeficiency viral infections increase the likelihood of secondary bacterial infections [23], [24]. Recently, Kubes et al. [25] demonstrated that feline neutrophils exh

• Zaragozic Acid A receptor br Results and discussion br Concl

  2022-04-19

  

  Results and discussion Conclusion In summary, we designed and discovered a series of novel GPR40 agonists containing 3,5-dimethylisoxazole with improved tPSA and ideal cLog P. Most of these compounds were confirmed as excellent GPR40 agonists in vitro. Especially, compound 11k exhibited robust

• Our previous study had shown that

  2022-04-19

  

  Our previous study had shown that silencing FFAR1 expression weakened the action of PIO in increasing insulin secretion in lipotoxic β Vincristine sulfate [6]. Resent research found that PIO promoted insulin secretion by upregulating FFAR1 [17]. Therefore, we presumed that FFAR1 may be involved in

• br Ferroptosis modulators With the recognition that the smal

  2022-04-19

  

  Ferroptosis modulators With the recognition that the small molecule erastin targets system xc- and thereby specifically triggers this form of death and that ferrostatin-1 prevents erastin-induced ferroptosis [2], it has become evident that ferroptosis is a druggable pathway with a number of tract

• PD PD L signaling is critical

  2022-04-19

  

  PD-1/PD-L1 signaling is critical for the induction of exhausted CD8+ T adenosine diphosphate synthesis during the tumor immune response (Barber et al., 2006; Wherry et al., 2007; Wherry and Kurachi,2015; Pauken and Wherry, 2015), but the relationship between PD-1/PD-L1 signaling and Fas/FasL signal

• The current lack of effective treatments for primary

  2022-04-19

  

  The current lack of effective treatments for primary or metastatic UM leaves a large therapeutic gap for patients and clinicians underscoring an urgent need for the identification of additional pharmacological targets for therapeutic intervention. As YAP-targeting strategies have remained elusive th

• In non Hodgkin lymphoma the catalytic

  2022-04-19

  

  In non-Hodgkin lymphoma the catalytic SET domain of the histone methyltransferase EZH2 is subject to recurrent heterozygous missense mutations . These alterations have been observed in ∼20% of patients with diffuse large B cell lymphoma (DLBCL) and ∼10% of patients with follicular lymphoma (FL). The

• Furthermore the immunoassays described in our study showed

  2022-04-19

  

  Furthermore, the immunoassays described in our study showed excellent concordance of more than 93.33% with the LAg-Avidity EIA (Table 2). Using a panel of samples obtained from HIV-1 seroconverters over the course of up to 602 days post-infection, the gp41 peptide-based MP3 or MP4 assay identified s

• Gardiquimod receptor In terms of outcome measures statistica

  2022-04-19

  

  In terms of outcome measures, statistically significant differences were only observed in need for invasive mechanical ventilation (23% vs 46%, p-value 0.005) and in-hospital mortality (13% vs 37%, p-value 0.002). Both these outcomes were still statistically significant following adjustment for conf

15911 records 439/1061 page Previous Next First page 上5页 436437438439440 下5页 Last page